Leucovorin: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "5 mg" to "5mg") |
Neil.m.young (talk | contribs) (Text replacement - "0 mg" to "0mg") |
||
| Line 7: | Line 7: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Fluorouracil adjuvant treatment, adv. colorectal CA | *Fluorouracil adjuvant treatment, adv. colorectal CA | ||
**high dose: | **high dose: 200mg/m^2 IV qd x5 days | ||
**low dose: | **low dose: 20mg/m^2 IV qd x5 days | ||
*Leucovorin rescue, high-dose methotrexate | *Leucovorin rescue, high-dose methotrexate | ||
| Line 14: | Line 14: | ||
**delayed late methotrexate elimination: 15mg PO/IM/IV q6h; Max: 25mg/dose PO, May give higher doses IM/IV | **delayed late methotrexate elimination: 15mg PO/IM/IV q6h; Max: 25mg/dose PO, May give higher doses IM/IV | ||
*Delayed early methotrexate elimination and/or acute renal injury: | *Delayed early methotrexate elimination and/or acute renal injury: 150mg IV q3h until methotrexate level <1 micromolar, then 15mg IV q3h | ||
*Leucovorin rescue, methotrexate overdose: | *Leucovorin rescue, methotrexate overdose: 10mg/m^2 PO/IM/IV q6h | ||
*Folate antagonist overdose | *Folate antagonist overdose | ||
**pemetrexed: | **pemetrexed: 50mg/m^2 IV q6h x8 days; Start: 100mg/m^2 IV x1 | ||
**pyrimethamine, trimethoprim: 5-15mg PO/IM/IV qd until hematopoiesis restored | **pyrimethamine, trimethoprim: 5-15mg PO/IM/IV qd until hematopoiesis restored | ||
| Line 27: | Line 27: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Leucovorin rescue, high-dose methotrexate | *Leucovorin rescue, high-dose methotrexate | ||
**normal methotrexate elimination: | **normal methotrexate elimination: 10mg/m^2 PO/IM/IV q6h x10 doses; Start: 24h after methotrexate start; Max: 25mg/dose PO | ||
**delayed late methotrexate elimination: | **delayed late methotrexate elimination: 10mg/m^2 PO/IM/IV q6h; Max: 25mg/dose PO | ||
**delayed early methotrexate elimination and/or acute renal injury: | **delayed early methotrexate elimination and/or acute renal injury: 100mg/m^2 IV q3h until methotrexate level <1 micromolar, then 10mg/m^2 IV q3 | ||
*Leucovorin rescue, methotrexate overdose: | *Leucovorin rescue, methotrexate overdose: 10mg/m^2 PO/IM/IV q6h | ||
*Folate antagonist overdose: 5-15mg PO/IM/IV qd until hematopoiesis restored | *Folate antagonist overdose: 5-15mg PO/IM/IV qd until hematopoiesis restored | ||
Revision as of 12:21, 19 July 2016
Administration
- Type: Antidote; Chemotherapy Modulating Agent; Rescue Agent (Chemotherapy)
- Dosage Forms: 5,10,15,25
- Routes of Administration: IV, IM
- Common Trade Names: Lederle Leucovorin
Adult Dosing
- Fluorouracil adjuvant treatment, adv. colorectal CA
- high dose: 200mg/m^2 IV qd x5 days
- low dose: 20mg/m^2 IV qd x5 days
- Leucovorin rescue, high-dose methotrexate
- normal methotrexate elimination: 15mg PO/IM/IV q6h x10 doses
- delayed late methotrexate elimination: 15mg PO/IM/IV q6h; Max: 25mg/dose PO, May give higher doses IM/IV
- Delayed early methotrexate elimination and/or acute renal injury: 150mg IV q3h until methotrexate level <1 micromolar, then 15mg IV q3h
- Leucovorin rescue, methotrexate overdose: 10mg/m^2 PO/IM/IV q6h
- Folate antagonist overdose
- pemetrexed: 50mg/m^2 IV q6h x8 days; Start: 100mg/m^2 IV x1
- pyrimethamine, trimethoprim: 5-15mg PO/IM/IV qd until hematopoiesis restored
- Megaloblastic anemia, folate-deficient: <1mg IM/IV qd
- Max: 1mg/day
Pediatric Dosing
- Leucovorin rescue, high-dose methotrexate
- normal methotrexate elimination: 10mg/m^2 PO/IM/IV q6h x10 doses; Start: 24h after methotrexate start; Max: 25mg/dose PO
- delayed late methotrexate elimination: 10mg/m^2 PO/IM/IV q6h; Max: 25mg/dose PO
- delayed early methotrexate elimination and/or acute renal injury: 100mg/m^2 IV q3h until methotrexate level <1 micromolar, then 10mg/m^2 IV q3
- Leucovorin rescue, methotrexate overdose: 10mg/m^2 PO/IM/IV q6h
- Folate antagonist overdose: 5-15mg PO/IM/IV qd until hematopoiesis restored
- Megaloblastic anemia, folate-deficient: <1mg IM/IV qd
- Max: 1mg/day
Special Populations
- Pregnancy Risk Factor: C
Renal Dosing
- Not defined
Hepatic Dosing
- Not defined
Contraindications
- Allergy to class/drug
- intrathecal administration
- caution if pernicious anemia
- caution if megaloblastic anemia, vitamin B12 deficient
- caution if vitamin B-12 deficiency
Adverse Reactions
Serious
- anaphylactoid reaction
- seizures
- syncope
Common
- urticaria
- nausea/vomiting (IV use)
Pharmacology
- Half-life: 6hr
- Metabolism: liver, GI, CYP450
- Excretion: Urine
Mechanism of Action
Comments
See Also
References
<Epocrates, UpToDate>
